{
    "clinical_study": {
        "@rank": "90590", 
        "arm_group": [
            {
                "arm_group_label": "Control: Standard Care", 
                "arm_group_type": "Other", 
                "description": "The control group will receive standard care (debridement, cleansing) and Profore\u00ae multi-layer compression therapy (replacing the wound contact layer with Telfa\u2122 Clear)."
            }, 
            {
                "arm_group_label": "ReCell", 
                "arm_group_type": "Experimental", 
                "description": "The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore\u00ae multi-layer compression therapy (replacing the wound contact layer with Telfa Clear)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomised, open label, controlled pilot study to evaluate the safety\n      and preliminary effectiveness of the ReCell Autologous Cell Harvesting Device (ReCell) for\n      the management of chronic leg ulcers associated with venous insufficiency. Outcome will be\n      compared between study participants receiving standard care (debridement, compression\n      therapy) and participants receiving ReCell in addition to standard care."
        }, 
        "brief_title": "A Pilot Trial of the Use of ReCell\u00ae Autologous Cell Harvesting Device for Venous Leg Ulcers", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Leg Ulcers", 
        "condition_browse": {
            "mesh_term": [
                "Leg Ulcer", 
                "Ulcer", 
                "Varicose Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Chronic venous leg ulcer (CEAP Clinical classification of 6)\n\n               -  Confirmed, treated venous reflux\n\n               -  No exposed tendon or bone\n\n               -  Ulcer is >4 weeks in duration\n\n               -  Ulcer surface area between 2cm2 and 80cm2\n\n          2. ABI \u2265 0.8\n\n          3. The patient is 18 years of age or older\n\n          4. The patient is willing to complete all follow-up evaluations required by the study\n             protocol\n\n          5. The patient is able to abstain from any other treatment of the ulcer for the duration\n             of the study, unless medically necessary\n\n          6. The patient agrees to abstain from enrollment in any other clinical trial for the\n             duration of the study\n\n          7. The patient is able to read and understand instructions and give voluntary written\n             informed consent\n\n          8. The patient is able and willing to follow the protocol requirements (including\n             compression therapy)\n\n        Exclusion Criteria:\n\n          1. Study treatment area has exposed bone or tendon\n\n          2. Poorly controlled diabetes\n\n          3. Arterial insufficiency (ABI < 0.8)\n\n          4. Pregnant/lactating females (self-reported or tested, per institutional requirements)\n\n          5. Subjects who have evidence of connective tissue disorders (e.g. vasculitis or\n             rheumatoid arthritis) under active treatment\n\n          6. The patient has an active wound infection requiring antibiotic therapy\n\n          7. The patient has had a prior surgical treatment of the ulcer\n\n          8. The patient is known to have a pre-existing condition that may interfere with wound\n             healing, e.g. malignancy, autoimmune disease, immunocompromised blood borne diseases,\n             the patient has AIDS, is HIV- or Hepatitis-C positive, or currently has a severe\n             dermatological disorder (e.g. severe psoriasis, epidermolysis bullosa, pyoderma\n             gangrenosum).\n\n          9. The patient is unable to follow the protocol\n\n         10. The patient is taking medication known to have an effect on wound healing (e.g.,\n             corticosteroids)\n\n         11. The patient has other concurrent conditions that in the opinion of the investigator\n             may compromise patient safety or study objectives\n\n         12. The patient has a known hypersensitivity to trypsin or compound sodium lactate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "65", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743053", 
            "org_study_id": "ReCell VLU Pilot Study"
        }, 
        "intervention": [
            {
                "arm_group_label": "ReCell", 
                "intervention_name": "Standard Care plus ReCell", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Control: Standard Care", 
                "intervention_name": "Standard Care", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 4, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark"
                    }, 
                    "name": "Odense University Hospital"
                }, 
                "investigator": {
                    "last_name": "Professor Finn Gottrup", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France"
                    }, 
                    "name": "H\u00f4pital Lapeyronie"
                }, 
                "investigator": {
                    "last_name": "Professor Luc T\u00e9ot", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Addenbrookes Hospital"
                }, 
                "investigator": {
                    "last_name": "Mr Paul Hayes", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "SHartwell@avitamedical.com", 
            "last_name": "Samantha Hartwell, PhD", 
            "phone": "44 (0)7771 332283"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Research Ethics Committee", 
                "Denmark: Ethics Committee", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to assess the difference in incidence of ulcer closure (investigator assessed as complete epithelialisation without drainage) between the ReCell group and the control group.", 
            "measure": "Wound healing", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743053"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Wound area\nWound volume\nPain\nRecurrence\nHealth-related Quality of Life", 
                "measure": "Wounds characterization/Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks)"
            }, 
            {
                "description": "- Dressing change", 
                "measure": "Dressing Change", 
                "safety_issue": "No", 
                "time_frame": "At each follow-up visit (1, 2, 4, 6, 8, 12, 24, 52 weeks) until healed"
            }
        ], 
        "source": "Avita Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Avita Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}